title: Standardized Mississippi Protocol treatment of 190 patients with HELLP syndrome: slowing disease progression and preventing new major maternal morbidity.
abstract: OBJECTIVE
  To evaluate the effectiveness of the Mississippi Protocol (MP) to treat HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome.
  
  
  METHODS
  Uniform early initiation of MP (corticosteroids, magnesium sulfate, systolic blood pressure control) was studied prospectively in patients admitted with severe preeclampsia/class 1 or class 2 HELLP syndrome.
  
  
  RESULTS
  One hundred and ninety patients between 2000 and 2007 received MP without suffering maternal death, stroke, or liver rupture. Only 39 of 163 patients (24%) not class 1 when MP began progressed to class 1 disease; only 18.2% of class 1 and 2.4% of class 2 subsequently developed major maternal morbidity.
  
  
  CONCLUSIONS
  Early initiation of MP inhibits HELLP syndrome disease progression and severity.
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, and the Biostatistics Center, University of Mississippi Medical Center, Jackson, MS 39216, USA. jnmartin@ob-gyn.umsmed.edu
authors.forename: James N
authors.initials: JN
authors.lastname: Martin
authors.forename: Michelle Y
authors.initials: MY
authors.lastname: Owens
authors.forename: Sharon D
authors.initials: SD
authors.lastname: Keiser
authors.forename: Marc R
authors.initials: MR
authors.lastname: Parrish
authors.forename: Kiran B
authors.initials: KB
authors.lastname: Tam Tam
authors.forename: Justin M
authors.initials: JM
authors.lastname: Brewer
authors.forename: Julie L
authors.initials: JL
authors.lastname: Cushman
authors.forename: Warren L
authors.initials: WL
authors.lastname: May
mesh_terms: D000046:Academic Medical Centers / Q000706:statistics & numerical data; D000328:Adult; D002985:Clinical Protocols; D018450:Disease Progression; D005260:Female; D017359:HELLP Syndrome / Q000628:therapy*; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult